Stay updated on Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page revision label was updated from v3.5.3 to v3.5.4, indicating a new deployment of the page.
    Difference
    0.0%
    Check dated 2026-05-15T13:58:53.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The site’s page interface/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” without any accompanying change to the displayed study record content.
    Difference
    0.0%
    Check dated 2026-04-24T05:50:28.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    A new site revision entry v3.5.2 was added and the older revision entry v3.5.0 was removed.
    Difference
    0.0%
    Check dated 2026-04-17T02:25:58.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Added a site revision label 'Revision: v3.5.0' and removed 'Revision: v3.4.3'.
    Difference
    0.0%
    Check dated 2026-03-19T04:30:31.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    Eligibility criteria updated to require at least one prior therapy after checkpoint inhibitors and to include relapse, replacing the previous requirement of at least two prior therapies and removing certain transplant/cytotoxic treatment exclusions.
    Difference
    0.3%
    Check dated 2026-03-11T23:37:39.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now displayed; the earlier government funding/operating status notice (Revision: v3.4.1) has been removed. This is an administrative update and does not affect the study details.
    Difference
    0.4%
    Check dated 2026-02-11T11:52:16.000Z thumbnail image

Stay in the know with updates to Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.